Video

Q&A With Gilmore O'Neill of Biogen International: Tecfidera as MS Treatment Leader

Author(s):

Chronic conditions like multiple sclerosis require constant monitoring by doctors and patients, As time goes on medication and treatment options may need to be changed. Tecfidera, one popular treatment option has become a popular choice in patient care.

Chronic conditions like multiple sclerosis require constant monitoring by doctors and patients, As time goes on medication and treatment options may need to be changed. Tecfidera, one popular treatment option has become a popular choice in patient care.

Gilmore O'Neill, MD, of Biogen International discussed what has made the medication a go to choice for doctors and patients alike during the American Academy of Neurology's annual meeeting in Washington, DC. O'Neill also discussed the safety profile for the medication and the advantages of Tecfidera being an oral treatment option.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.